ClinicalTrials HQ

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Recruiting · NCT06433947 · Registry updated 2026-05-19
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple MyelomaBlood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic diseaseRecruitingPhase 12026-05-19NCT06433947

1 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Opna Bio LLC1

12 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Banner MD AndersonGilbertUnited States6
Dana Farber Cancer InstituteBostonUnited States300
Emory Winchip Cancer CenterAtlantaUnited States1
Fred Hutchinson Cancer CenterSeattleUnited States250
Huntsman Cancer Center Institute University of UtahSalt Lake CityUnited States1
Karmanos Cancer InstituteDetroitUnited States153
Stanford Cancer InstituteStanfordUnited States19
START MidwestGrand RapidsUnited States79
UC San Diego Moores Cancer CenterLa JollaUnited States4
University of Kansas Clinical Research CenterWestwoodUnited States2
University of North Carolina Hospitals at HillsboroughChapel HillUnited States1
University of Rochester Medical CenterRochesterUnited States162